Valirx (VAL)

 

Latest News

VAL201 update

RNS Number: 3340R ValiRx PLC 20 September 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") VAL201 update The Company notes speculation as to the status of its VAL201 clinical trial and confirms that the trial is ongoing and looks forward to updating the market in due course. Further details of the trial can be found at https://www.clinicaltrial...

Issue of Equity

RNS Number: 0927R ValiRx PLC 19 September 2017 19 September 2017 ValiRx Plc ("ValiRx" or the "Company") Issue of Equity ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, is pleased to announce a placing to raise 0.5 million. The Company has raised 0.5 million of gross proceeds through the issue of 50,000,000 new ordinary shares at a price of 1 pe...

Hardman Research: GeneICE and VAL101 progress

RNS Number: 6222Q ValiRx PLC 13 September 2017 Hardman Research: GeneICE and VAL101 progress GeneICE and VAL101 progress: ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company's two leading assets are in clinical trials: ...

ValiRx reports good progress in developing GeneICE technology platform

ValiRx reported a period of continued good progress in the development of its GeneICE technology platform, in which "re...

All News

DateHeadlineSource
20-09-17VAL201 updateRNS
19-09-17Issue of EquityRNS
13-09-17Hardman Research: GeneICE and VAL101 progressRNS
07-09-17ValiRx reports good progress in developing GeneICE technology platformStockMarketWire
07-09-17GeneICE & VAL101 UpdateRNS
07-09-17ValiRx - GeneICE & VAL101 UpdateBRR Media
11-08-17Convertible Loan FacilityRNS
02-08-17Conversion of Loan NoteRNS
28-07-17ValiRx signs first product licensing agreementStockMarketWire
28-07-17Licencing AgreementRNS
22-06-17Formation of & Appointments to an Advisory BoardRNS
15-06-17ValiSeek Development Update - Recruitment ClosesRNS
15-06-17ValiRx - ValiSeek Clinical Development UpdateBRR Media
01-06-17ValiRx updates on Yorkville CLN ConversionStockMarketWire
01-06-17Yorkville CLN ConversionRNS
31-05-17Hardman Research:Developing novel cancer therapiesRNS
30-05-17All resolutions passed at AGM of ValiRxStockMarketWire
30-05-17Result of AGMRNS
24-05-17ValiSeek's patent allowed in AustraliaStockMarketWire
24-05-17NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCERNS
08-05-17Broker Forecast - Beaufort Securities issues a broker note on ValiRx PLCStockMarketWire
08-05-17ValiRx - Final Results BRR Media
05-05-17Notice of AGMRNS
05-05-17ValiRx widens FY pretax loss from continuing ops.StockMarketWire
05-05-17Final ResultsRNS
27-04-17Re: SHARES Magazine Supplement on ValiRx websiteRNS
19-04-17Change of Registered OfficeRNS
15-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
15-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
15-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
15-03-17Director/PDMR ShareholdingRNS
08-03-17ValiSeek Clinical Development UpdateRNS
08-03-17ValiRX - Projects updateBRR Media
02-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
02-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
02-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
02-03-17Director/PDMR ShareholdingRNS
01-03-17ValiRx raises £1.16m via placingStockMarketWire
01-03-17Placing to raise ?1.16m and Proposed SubscriptionRNS
28-02-17Publication of Peer-Reviewed Articles on VAL401RNS

RSS feeds

  • Editorial news feed for LSE:VAL Editorial
  • Regulatory news feed for LSE:VAL Regulatory